NCT05498220 2026-04-16
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
Clinical Trials
17 trialsNCT04268277 2026-02-27
Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
University of Ulm
Phase 2 Terminated
NCT04464798 2025-04-29
A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
Celgene
Phase 1 Terminated
NCT02384954 2024-07-03
QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab
Altor BioScience
Phase 1/2 Terminated
NCT03422523 2022-08-22
ARGO
University Hospital Southampton NHS Foundation Trust
Phase 2 Terminated
NCT03189836 2021-10-11
Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma
Cogent Biosciences, Inc.
Phase 1 Terminated
NCT01729104 2019-10-22
Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00949988 2019-08-14
BMS-CA180105
University of California, San Diego
Phase 1/2 Terminated
NCT02983097 2018-01-19
R²-DHAP
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Phase 1/2 Terminated
NCT00617929 2017-12-28
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT01173679 2017-04-14
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL
Massachusetts General Hospital
Phase 2 Terminated
NCT00384150 2015-11-26
Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)
Biogen
Phase 3 Terminated
NCT00363636 2015-10-02
A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)
Biogen
Phase 3 Terminated
NCT00087009 2013-03-19
Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center
Phase 1 Terminated
NCT00036855 2013-01-17
Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00968331 2012-08-27
Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
University of Bologna
Phase 2 Terminated
NCT00180895 2006-09-11
Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated